Abstract: OBJECTIVE To establish a specific HPLC method for the determination of ginsenoside Rb1, Rb2 and Rg1 in rat plamsa, and study the pharmacokinetic characteristics of ginsenoside in chronic atrophic gastritis rats before and after compatibility with atractylodes volatile oil. METHODS SD rats were randomly divided into 4 groups:the ginseng single-use normal group and the ginseng single-use model group(ginsenoside 292 mg·kg^-1), the ginseng compatibility normal group and the ginseng compatibility model group(ginsenosides 292 mg·kg^-1, atractylodes volatile oil 0.1 mL·kg^-1). Plasma samples were collected from the orbital veins of rats at different time points after drug administration. The blood concentration of each component was determined by HPLC and its pharmacokinetic parameters were calculated by using Winnolin 6.3 software. RESULTS Compared with the single-use normal rats group, the C_max and AUC values of ginsenoside Rb1 in single-use model group rats were decreased, T_max, T_1/2 and MRT were prolonged, the AUC values of ginsenoside Rb2 and Rg1 were increased; C_max and AUC values of ginsenosides Rb1, Rb2 and Rg1 were increased in compatibility normal group rats, whereas T_max, T_1/2 and MRT were shortened. Compared with the single-use model group rats, C_max and AUC values of ginsenosides Rb1 and Rg1 in compatibility model group rats were increased, T_max, T_1/2 and MRT were decreased. CONCLUSION At the same dose, the body's absorption and metabolism of ginsenosides showed a slow trend under the disease state, and the compatibility could accelerate the absorption of saponins in the body and accelerate the elimination of metabolism. It provides a reference for the clinical use of ginseng.